Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

345
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
345
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

314
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
314
Relative Risk01:12

Relative Risk

1.6K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiologists' perspectives on sociocultural and structural factors shaping cardiovascular genetic testing.

medRxiv : the preprint server for health sciences·2026
Same author

Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial.

Lancet (London, England)·2026
Same author

COMPREHENSIVE GENETIC INVESTIGATION REVEALS HETEROGENEOUS PATHWAYS TO OBSTRUCTIVE SLEEP APNEA.

medRxiv : the preprint server for health sciences·2026
Same author

The Cost-Effectiveness of Gastric Cancer Screening and Surveillance Among Average-Risk and Risk-Stratified Populations.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Leveraging genomic biobanks to enhance genetic testing outcomes for kidney disease.

medRxiv : the preprint server for health sciences·2025
Same author

Performance of recommended management among pediatric patients identified through genomic screening.

Translational behavioral medicine·2025
Same journal

Sociodemographic trends in prostate cancer: Insights from the all of Us research program.

JNCI cancer spectrum·2026
Same journal

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

JNCI cancer spectrum·2026
Same journal

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

JNCI cancer spectrum·2026
Same journal

Response to bates.

JNCI cancer spectrum·2026
Same journal

RE: Rural-urban disparities and trends in cancer screening: an analysis of Behavioral Risk Factor Surveillance System data (2018-2022).

JNCI cancer spectrum·2026
Same journal

Pandemic-era increases in late-stage pediatric cancer diagnoses, 2020-2022.

JNCI cancer spectrum·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

589

Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future

Steffie K Naber1, Suman Kundu1, Karen M Kuntz1

  • 1See the Notes section for the full list of authors' affiliations.

JNCI Cancer Spectrum
|February 7, 2020
PubMed
Summary
This summary is machine-generated.

Polygenic risk-based screening for colorectal cancer (CRC) is not yet cost-effective compared to uniform screening. Improvements in polygenic test accuracy, reduced costs, or increased participation could make it viable.

More Related Videos

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.3K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

440

Related Experiment Videos

Last Updated: Dec 29, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

589
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.3K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

440

Area of Science:

  • Oncology
  • Genetics
  • Health Economics

Background:

  • Uniform colonoscopy screening effectively reduces colorectal cancer (CRC) mortality.
  • Risk-based screening strategies may offer improved efficiency over uniform approaches.
  • The cost-effectiveness of polygenic risk-based CRC screening requires investigation.

Purpose of the Study:

  • To evaluate if CRC screening based on polygenic risk is a cost-effective alternative to current uniform screening.
  • To determine the conditions under which polygenic risk-based screening could become cost-effective.

Main Methods:

  • The MISCAN-Colon model simulated a US cohort of 40-year-olds.
  • Uniform screening involved colonoscopies at ages 50, 60, and 70.
  • Risk-stratified screening utilized polygenic testing (AUC 0.60-0.80) to optimize screening parameters (age, interval).

Main Results:

  • Optimal risk-stratified screening varied from one colonoscopy (age 60) for lowest risk to six (ages 40-80) for highest risk.
  • Risk-stratified screening increased costs by $59 per person while maintaining health benefits.
  • Cost-effectiveness is achievable if AUC > 0.65, polygenic test cost < $141, or participation increases by 5%.

Conclusions:

  • Currently, polygenic risk-based CRC screening is not cost-effective compared to uniform screening.
  • Future cost-effectiveness depends on AUC increases (>0.05), polygenic testing cost reductions (>30%), or adherence increases (>5%).